ATE287881T1 - 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin v1b und v1a rezeptoren - Google Patents

1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin v1b und v1a rezeptoren

Info

Publication number: ATE287881T1
Authority: AT; Austria
Prior art keywords: vasopressin; indol; dihydro; ligands; arginine
Prior art date: 2000-06-19

Application number

AT01947534T

Other languages

English (en)

Inventor

Richard Roux

Gal Claudine Serradeil-Le

Jean Wagnon

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-19

Filing date

2001-06-19

Publication date

2005-02-15

2001-06-19 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2005-02-15 Application granted granted Critical

2005-02-15 Publication of ATE287881T1 publication Critical patent/ATE287881T1/de

Links

101800001144 Arg-vasopressin Proteins 0.000 title 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 title 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title 1
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
239000003446 ligand Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)

AT01947534T 2000-06-19 2001-06-19 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin v1b und v1a rezeptoren ATE287881T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0007885A FR2810320B1 (fr)	2000-06-19	2000-06-19	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
PCT/FR2001/001919 WO2001098295A1 (fr)	2000-06-19	2001-06-19	Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine

Publications (1)

Publication Number	Publication Date
ATE287881T1 true ATE287881T1 (de)	2005-02-15

Family

ID=8851468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01947534T ATE287881T1 (de)	2000-06-19	2001-06-19	1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin v1b und v1a rezeptoren

Country Status (14)

Country	Link
US (2)	US6864277B2 (de)
EP (1)	EP1296976B1 (de)
JP (1)	JP2004502654A (de)
AR (1)	AR029942A1 (de)
AT (1)	ATE287881T1 (de)
AU (1)	AU2001269198A1 (de)
DE (1)	DE60108633T2 (de)
DK (1)	DK1296976T3 (de)
ES (1)	ES2236260T3 (de)
FR (1)	FR2810320B1 (de)
HU (1)	HUP0303118A3 (de)
PT (1)	PT1296976E (de)
TW (1)	TWI287011B (de)
WO (1)	WO2001098295A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2804114B1 (fr) *	2000-01-25	2002-03-08	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP4618127B2 (ja) *	2003-08-28	2011-01-26	大正製薬株式会社	１，３−ジヒドロ−２ｈ−インドール−２−オン誘導体
US20050070718A1 (en) *	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en)	2003-09-30	2013-11-12	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20080227802A1 (en) *	2004-12-27	2008-09-18	Kyoto University	Agent For Suppressing Development of Tolerance to Narcotic Analgesics
WO2006080574A1 (ja) *	2005-01-28	2006-08-03	Taisho Pharmaceutical Co., Ltd.	１，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
DE102005014936A1 (de)	2005-03-24	2006-12-14	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
WO2006100082A2 (de) *	2005-03-24	2006-09-28	Abbott Gmbh & Co. Kg	Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102005014904A1 (de) *	2005-03-26	2007-02-01	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
CN101336239A (zh) *	2005-12-02	2008-12-31	艾博特股份有限两合公司	经取代的羟吲哚衍生物，含有该衍生物的药物及其用途
DE102006040915A1 (de) *	2006-08-26	2008-03-20	Abbott Gmbh & Co. Kg	Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
TWI403508B (zh) *	2006-08-26	2013-08-01	Abbott Gmbh & Co Kg	經取代苯并咪唑酮衍生物、包含其之醫藥品及其用途
US8486979B2 (en)	2006-12-12	2013-07-16	Abbvie Inc.	1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en)	2006-12-12	2008-07-10	Abbott Laboratories	Pharmaceutical compositions and their methods of use
UY30846A1 (es) *	2006-12-30	2008-07-31	Abbott Gmbh & Amp	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
KR20100097195A (ko)	2007-12-07	2010-09-02	애보트 게엠베하 운트 콤파니 카게	５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
EP2231644B1 (de)	2007-12-07	2014-01-15	AbbVie Deutschland GmbH & Co KG	5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
JP5701607B2 (ja)	2007-12-07	2015-04-15	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
WO2010009775A1 (de)	2007-12-07	2010-01-28	Abbott Gmbh & Co. Kg	Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MY157425A (en)	2007-12-27	2016-06-15	Abbvie Deutschland	Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
FR2927625B1 (fr) *	2008-02-19	2010-03-12	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr)	2008-04-21	2010-05-14	Sanofi Aventis	Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
EP2435080A2 (de)	2009-05-29	2012-04-04	Abbott Laboratories	Pharmazeutische zusammensetzungen zur schmerzbehandlung
US20230391721A1 (en) *	2020-10-23	2023-12-07	The Board Of Trustees Of The University Of Illinois	Anticancer compounds selective for er-positive cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338755A (en) *	1990-07-31	1994-08-16	Elf Sanofi	N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2714378B1 (fr)	1993-12-24	1996-03-15	Sanofi Sa	Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.

2000
- 2000-06-19 FR FR0007885A patent/FR2810320B1/fr not_active Expired - Fee Related
2001
- 2001-06-14 TW TW090114443A patent/TWI287011B/zh not_active IP Right Cessation
- 2001-06-19 US US10/311,435 patent/US6864277B2/en not_active Expired - Fee Related
- 2001-06-19 WO PCT/FR2001/001919 patent/WO2001098295A1/fr not_active Ceased
- 2001-06-19 ES ES01947534T patent/ES2236260T3/es not_active Expired - Lifetime
- 2001-06-19 AT AT01947534T patent/ATE287881T1/de active
- 2001-06-19 EP EP01947534A patent/EP1296976B1/de not_active Expired - Lifetime
- 2001-06-19 DK DK01947534T patent/DK1296976T3/da active
- 2001-06-19 PT PT01947534T patent/PT1296976E/pt unknown
- 2001-06-19 AU AU2001269198A patent/AU2001269198A1/en not_active Abandoned
- 2001-06-19 DE DE60108633T patent/DE60108633T2/de not_active Expired - Lifetime
- 2001-06-19 JP JP2002504251A patent/JP2004502654A/ja active Pending
- 2001-06-19 AR ARP010102900A patent/AR029942A1/es unknown
- 2001-06-19 HU HU0303118A patent/HUP0303118A3/hu unknown
2005
- 2005-02-24 US US11/064,896 patent/US7425566B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2004502654A (ja)	2004-01-29
US7425566B2 (en)	2008-09-16
TWI287011B (en)	2007-09-21
HUP0303118A3 (en)	2007-08-28
FR2810320B1 (fr)	2002-08-23
US20030162767A1 (en)	2003-08-28
EP1296976B1 (de)	2005-01-26
FR2810320A1 (fr)	2001-12-21
AU2001269198A1 (en)	2002-01-02
WO2001098295A1 (fr)	2001-12-27
PT1296976E (pt)	2005-06-30
US6864277B2 (en)	2005-03-08
AR029942A1 (es)	2003-07-23
ES2236260T3 (es)	2005-07-16
HUP0303118A2 (hu)	2004-01-28
DE60108633D1 (de)	2005-03-03
DK1296976T3 (da)	2005-05-23
EP1296976A1 (de)	2003-04-02
DE60108633T2 (de)	2006-03-23
US20050176770A1 (en)	2005-08-11

Legal Events

Date

Code

Title

Description

2005-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1296976

Country of ref document: EP

Publication	Publication Date	Title
ATE269326T1 (de)	2004-07-15	1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
ATE287881T1 (de)	2005-02-15	1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin v1b und v1a rezeptoren
ATE267192T1 (de)	2004-06-15	1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
ATE282593T1 (de)	2004-12-15	Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
DE60135239D1 (de)	2008-09-18	Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
ATE514676T1 (de)	2011-07-15	Ionisierbare indolinon derivate und deren verwendung als ptk liganden
ATE369368T1 (de)	2007-08-15	Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
DE60113719D1 (de)	2006-02-09	Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE69723446D1 (de)	2003-08-14	Oxindole derivate
DE69925730D1 (de)	2005-07-14	4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
ATE330955T1 (de)	2006-07-15	Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4.
ATE279396T1 (de)	2004-10-15	Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden
DE60001840D1 (de)	2003-04-30	Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
IT1313625B1 (it)	2002-09-09	Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
ATE407131T1 (de)	2008-09-15	Substituierte bipiperidine -zwischenverbindungen und deren derivate
DE59912473D1 (de)	2005-09-29	2-phenylbenzimidazole und 2-phenylindole, deren herstellung und anwendung
DE69605430D1 (de)	2000-01-05	Chinolin-2-on derivate als serotonin antagonisten
ATE309225T1 (de)	2005-11-15	Substituierte chinazoline derivate
ATE254621T1 (de)	2003-12-15	Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
ATE329908T1 (de)	2006-07-15	Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
ATE353881T1 (de)	2007-03-15	1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
ATE260258T1 (de)	2004-03-15	Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
ATE252079T1 (de)	2003-11-15	Indolderivate und deren verwendung als 5ht2a liganden
DE69803689D1 (de)	2002-03-14	8-azabicyclo(3.2.1)0ctan-3-methanaminderivate als liganden der dopamin-rezeptoren d2 und d3 und der serotonin-rezeptoren 5ht1a und 5ht2
ATE353325T1 (de)	2007-02-15	4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten